Eric Jia-Sobota, Founder, Author at EverGlade Consulting

Eric Jia-Sobota, Founder

Eric Jia-Sobota is the National Leader of EverGlade’s Consulting Practice and the Founder of the Company. Eric’s consulting experience spans almost two decades across a breadth of industries, including, Federal Contracting, Life Sciences, Nonprofit, Technology, Construction, Healthcare, and others. View Eric's resume at https://ericjia-sobota.com/

Eric Jia-Sobota

ASPR RFI on Essential Medicines Industrial Base

Leave a Comment / ASPR-IBx, Life Sciences / By

ASPR Industrial Base Management and Supply Chain Request for Information (RFI) Strengthening the U.S. Pharmaceutical Supply Chain: ASPR’s Essential Medicines RFI The U.S. Department of Health and Human Services (HHS), through its Administration for Strategic Preparedness and Response (ASPR), recently issued a Request for Information (RFI) to industry partners regarding domestic manufacturing capabilities for essential […]

ASPR RFI on Essential Medicines Industrial Base Read More »

NIH Guidance on International Subcontracting

Leave a Comment / Life Sciences, NIH / By

Maximizing the Value of Foreign Collaborations While Safeguarding U.S. Investments The National Institutes of Health (NIH), the nation’s primary medical research agency, recently issued guidance on the use of international subcontractors in NIH-funded research. This announcement reflects NIH’s dual mission: advancing health outcomes for Americans while ensuring responsible stewardship of U.S. taxpayer dollars. While global

NIH Guidance on International Subcontracting Read More »

The NIH’s Strategic Plan for Autoimmune Disease Research

Leave a Comment / Life Sciences, NIH / By

Enhancing Innovation, Collaboration, and Impact Autoimmune diseases are one of the most significant and complex public health challenges of our time. Affecting an estimated 23.5 to 50 million Americans, these conditions range from rheumatoid arthritis and type 1 diabetes to multiple sclerosis and lupus, impacting nearly every organ system and disproportionately affecting women (over 80%

The NIH’s Strategic Plan for Autoimmune Disease Research Read More »

NIH’s New Policy on AI and Proposal Limits: What You Need to Know

Leave a Comment / Life Sciences, NIH / By

NIH just released NOT-OD-25-132: “Supporting Fairness and Originality in NIH Research Applications.” There are two major changes that will shape how you plan and submit proposals beginning September 25, 2025: Originality & AI: NIH reiterates that applications must be the investigators’ original work and flags risks from AI-generated text (e.g., plagiarism, fabricated citations). Institutions should

NIH’s New Policy on AI and Proposal Limits: What You Need to Know Read More »

BARDA’s mAb “Smart Manufacturing” Opportunity

Leave a Comment / BARDA, Life Sciences / By

Background The Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) has released a Draft Statement of Objectives (SOO) for feedback to help refine requirements for the upcoming “Smart Manufacturing” solicitation aiming to support the development of advanced monoclonal antibody (mAb) manufacturing and development techniques. The solicitation’s overarching

BARDA’s mAb “Smart Manufacturing” Opportunity Read More »

DOE unveils $1B in critical mineral funding

Leave a Comment / DOE, Emerging Technologies / By

Introduction The U.S. Department of Energy (DOE) has announced nearly $1 billion in funding to strengthen domestic critical minerals supply chains. This initiative targets mining, processing, and manufacturing technologies for essential materials such as rare earths, battery components, and specialty elements. It represents a major opportunity for companies prepared to advance clean energy, semiconductors, and

DOE unveils $1B in critical mineral funding Read More »

Inside the New Executive Order on Strategic API Reserves

Leave a Comment / ASPR-IBx, Life Sciences / By

Introduction On August 13, 2025, President Trump signed a sweeping Executive Order titled “Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve.” The order addresses a long-standing vulnerability in the U.S. healthcare system, the nation’s heavy reliance on foreign suppliers for the active pharmaceutical ingredients (APIs) that make up the

Inside the New Executive Order on Strategic API Reserves Read More »

DTRA’s “Plume” RFI for Marine Toxin Aerosol Exposure Models

Leave a Comment / DTRA, Life Sciences / By

Advancing Countermeasures for Marine Toxin Threats The Defense Threat Reduction Agency (DTRA), through its Research and Development Chemical and Biological Technologies Directorate in support of the Joint Science and Technology Office (JSTO), has issued a Request for Information (RFI) titled “Plume”. This initiative seeks information on the capabilities and availability of suitable animal models for

DTRA’s “Plume” RFI for Marine Toxin Aerosol Exposure Models Read More »

Navigating the SF-1408: A Guide to Pre-Award Accounting System Approval

Leave a Comment / Guides, Life Sciences / By

For companies eager to break into the federal market, the compliance landscape can feel like a maze of unfamiliar acronyms and requirements. One of the earliest and most critical checkpoints in this journey is the SF-1408: Pre-Award Survey of Prospective Contractor’s Accounting System. If you are bidding on a cost-reimbursement or time-and-materials contract, you will

Navigating the SF-1408: A Guide to Pre-Award Accounting System Approval Read More »

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates

Leave a Comment / BARDA, Life Sciences / By

As the global health landscape evolves, so too must the United States’ ability to respond rapidly to biological threats. To strengthen its readiness posture, the Biomedical Advanced Research and Development Authority (BARDA), in coordination with the Administration for Strategic Preparedness and Response (ASPR), has released a new opportunity under the BioMaP Consortium OT Vehicle. This

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates Read More »

DTRA RAVEN Program

DTRA’s Reimagining the Next Generation of Biodefense Vaccines

Leave a Comment / DTRA, Life Sciences / By

Reimagining the Next Generation of Biodefense Vaccines: DTRA’s RAVEN Opportunity The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO) and the Research and Development-Chem/Bio Medical Vaccines (RD-CBMV) division, has launched the Reimagining Available Vaccines and Envisioning Novelty (RAVEN) initiative. This forward-looking program is designed to modernize the nation’s medical countermeasure

DTRA’s Reimagining the Next Generation of Biodefense Vaccines Read More »

JPEO RFI u.s. military protective systems

U.S. Army Seeks Breakthrough Concepts to Combat Contaminant Infiltration in Protective Systems

Leave a Comment / JPEO, Life Sciences / By

Overview In a Request for Information (RFI), the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Protection (JPM CBRN P), has called on industry, academia, and non-traditional innovators to help reimagine how protective gear prevents the infiltration of harmful airborne particles and vapors. This initiative aims to address a longstanding issue known as the

U.S. Army Seeks Breakthrough Concepts to Combat Contaminant Infiltration in Protective Systems Read More »

Scroll to Top